Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796510 · ClinicalTrials.gov registry record · Phase 3
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT00796510 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 3 participants.
The verdict
NCT00796510, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.
Interventions
- DRUG Sitaxsentan
- DRUG Sitaxsentan and Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796510
The ClinicalTrials.gov registry entry for NCT00796510 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitaxsentan is the first listed.
NCT00796510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796510 about?
NCT00796510 is a clinical study titled "Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety". As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.
What is the current status of trial NCT00796510?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2010-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00796510?
The interventions under investigation include: Sitaxsentan (DRUG), Sitaxsentan and Sildenafil (DRUG).
Who is sponsoring clinical trial NCT00796510?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.